JP2020524993A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524993A5
JP2020524993A5 JP2019568601A JP2019568601A JP2020524993A5 JP 2020524993 A5 JP2020524993 A5 JP 2020524993A5 JP 2019568601 A JP2019568601 A JP 2019568601A JP 2019568601 A JP2019568601 A JP 2019568601A JP 2020524993 A5 JP2020524993 A5 JP 2020524993A5
Authority
JP
Japan
Prior art keywords
synthetic
cron
existent
nucleic acid
orf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019568601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524993A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037379 external-priority patent/WO2018232017A1/en
Publication of JP2020524993A publication Critical patent/JP2020524993A/ja
Publication of JP2020524993A5 publication Critical patent/JP2020524993A5/ja
Priority to JP2022187239A priority Critical patent/JP2023010961A/ja
Priority to JP2024069618A priority patent/JP2024087003A/ja
Withdrawn legal-status Critical Current

Links

JP2019568601A 2017-06-13 2018-06-13 クロンを含む組成物及びその使用 Withdrawn JP2020524993A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022187239A JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762518898P 2017-06-13 2017-06-13
US62/518,898 2017-06-13
US201762597387P 2017-12-11 2017-12-11
US62/597,387 2017-12-11
US201862676730P 2018-05-25 2018-05-25
US62/676,730 2018-05-25
PCT/US2018/037379 WO2018232017A1 (en) 2017-06-13 2018-06-13 Compositions comprising curons and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022187239A Division JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2020524993A JP2020524993A (ja) 2020-08-27
JP2020524993A5 true JP2020524993A5 (enExample) 2021-07-26

Family

ID=62846247

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019568601A Withdrawn JP2020524993A (ja) 2017-06-13 2018-06-13 クロンを含む組成物及びその使用
JP2022187239A Withdrawn JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A Withdrawn JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022187239A Withdrawn JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A Withdrawn JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Country Status (11)

Country Link
US (4) US20200123203A1 (enExample)
EP (1) EP3638797A1 (enExample)
JP (3) JP2020524993A (enExample)
KR (2) KR20250028508A (enExample)
CN (1) CN111108208A (enExample)
AU (2) AU2018285860A1 (enExample)
BR (1) BR112019026226A2 (enExample)
CA (1) CA3066750A1 (enExample)
IL (1) IL271275B2 (enExample)
MX (2) MX2019015018A (enExample)
WO (1) WO2018232017A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US20230048858A1 (en) * 2018-12-12 2023-02-16 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering secreted therapeutic modalities
CA3121528A1 (en) * 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
EP3894567A2 (en) * 2018-12-12 2021-10-20 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering intracellular therapeutic modalities
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
AU2021288320A1 (en) * 2020-06-12 2023-01-19 Flagship Pioneering Innovations V, Inc. Tandem anellovirus constructs
KR20230036109A (ko) * 2020-06-12 2023-03-14 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 바큘로바이러스 발현 시스템
KR20230041686A (ko) * 2020-06-17 2023-03-24 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US12018254B2 (en) * 2020-07-27 2024-06-25 Wisconsin Alumni Research Foundation Methods of making unbiased phage libraries
CA3206361A1 (en) * 2020-12-23 2022-06-30 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
WO2022170195A1 (en) * 2021-02-08 2022-08-11 Flagship Pioneering Innovations V, Inc. Hybrid aav-anellovectors
US20240197823A1 (en) * 2021-02-12 2024-06-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cationic antimicrobial peptides and uses thereof
WO2023069948A1 (en) * 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR751473A (fr) * 1932-06-01 1933-09-04 Poste d'incendie
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US7838658B2 (en) 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
WO2010099510A2 (en) 2009-02-27 2010-09-02 The Administrators Of The Tulane Educational Fund Amino acid-based compounds, their methods of use, and methods of screening
EP2449106B1 (en) 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US9676828B2 (en) * 2010-06-23 2017-06-13 Deutsches Krebsforschungszentrum Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
RU2623161C2 (ru) * 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
WO2015089419A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Similar Documents

Publication Publication Date Title
US11446344B1 (en) Anellovirus compositions and methods of use
JP2022513797A5 (enExample)
CN111108208A (zh) 包含愈合子的组合物及其用途
JP2022512395A (ja) 分泌治療モダリティを送達するためのアネロソーム
JP2007511216A (ja) 変異ウイルス
JP2022512395A5 (enExample)
CN110393791B (zh) hnRNPA2B1的抗感染作用及其应用
JP2022513797A (ja) アネロソーム及び使用の方法
WO2019080537A1 (zh) 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
KR20250114450A (ko) 암호화 리보핵산의 기관 보호적 발현 및 조절을 위한 조성물 및 방법
JP2022514501A5 (enExample)
JP2022514501A (ja) 細胞内治療モダリティを送達するためのアネロソーム
WO2021253733A1 (en) Construct and use thereof
CN119736261A (zh) 溶瘤病毒及其应用
US20240050580A1 (en) Compositions targeting tumor associated macrophages and methods using same
JP7047238B2 (ja) 安全性及び抗がん効果が改善した腫瘍溶解性ウイルス
US11524047B2 (en) Pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer including CHI3L1 inhibitor as active ingredient
CN115989321B (zh) 病毒制剂、用于配制病毒制剂的溶液及其用途
CN111041001B (zh) 治疗kras突变型肿瘤的安全型柯萨奇病毒及其药物组合物
JPWO2005103237A1 (ja) 組換え単純ヘルペスウイルスの作製方法
Ni et al. Antitumor efficacy of CRISPR/Cas9–engineered ICP6 mutant herpes simplex viruses in a mouse xenograft model for lung adenocarcinoma
US20170319639A1 (en) Oncolytic viruses & methods of use thereof
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
CN114096661B (zh) 改进了安全性及抗肿瘤效果的溶瘤病毒
CN1242051A (zh) 用于肿瘤治疗和预防的致细胞病变病毒